Compare CELC & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CELC | BBUC |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2017 | 2015 |
| Metric | CELC | BBUC |
|---|---|---|
| Price | $136.90 | $33.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $112.56 | $41.00 |
| AVG Volume (30 Days) | ★ 1.0M | 220.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $720.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.26 | $27.64 |
| 52 Week High | $151.02 | $38.25 |
| Indicator | CELC | BBUC |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 47.82 |
| Support Level | $100.58 | $30.99 |
| Resistance Level | $151.02 | $37.44 |
| Average True Range (ATR) | 8.56 | 1.25 |
| MACD | -0.13 | -0.14 |
| Stochastic Oscillator | 54.66 | 60.25 |
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.